<DOC>
	<DOCNO>NCT01051505</DOCNO>
	<brief_summary>The purpose study explore safety tolerability AZD5069 steady-state , follow twice day oral dose healthy subject . AZD5069 develop AstraZeneca study carry behalf sponsor Quintiles Drug Research Unit Guy 's Hospital , London . This second time AZD5069 administer human clinical trial . We conduct study determine whether AZD5069 safe well tolerate healthy male female different dose level 8-day dosing period . We also study quickly AZD5069 absorb clear body . It plan 3 dose group study group consist 12 volunteer , 9 receive active drug 3 receiving placebo . The study involve 3 visit approximately 8 week , include 1 residential visit last 10 night follow .</brief_summary>
	<brief_title>A Study Assess Safety , Tolerability , Pharmacokinetics ( PK ) Pharmacodynamics ( PD ) Multiple Ascending Doses AZD5069 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Provision sign date , write informed consent Have body mass index ( BMI ) 18 30 kg/m2 inclusive weigh least 50 kg 100 kg Healthy male female ( non child bear potential ) volunteer suitable vein cannulation repeat venepuncture Subjects must clinically significant disease disorder , , opinion Investigator , may either put subject risk participation study , influence result , subject ability participate Subjects must history gastrointestinal , liver kidney disease , condition know interfere drug absorb , use eliminate body Subjects must significant illness medical/surgical procedure injuries 4 week administration investigational product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Phase I</keyword>
	<keyword>multiple ascend dose</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Healthy Volunteer</keyword>
</DOC>